Article info

Download PDFPDF
Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study

Authors

  • W-M Chan Hong Kong Eye Hospital, Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong, People’s Republic of China Prince of Wales Hospital, Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong, People’s Republic of China Hong Kong Sanatorium & Hospital, Hong Kong, People’s Republic of China PubMed articlesGoogle scholar articles
  • T Y Y Lai Hong Kong Eye Hospital, Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong, People’s Republic of China PubMed articlesGoogle scholar articles
  • D T L Liu Prince of Wales Hospital, Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong, People’s Republic of China PubMed articlesGoogle scholar articles
  • D S C Lam Hong Kong Eye Hospital, Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong, People’s Republic of China PubMed articlesGoogle scholar articles
  1. Dr W-M Chan, Department of Ophthalmology, Hong Kong Sanatorium & Hospital, 8/F, Li Shu Pui Block, 2 Village Road, Happy Valley, Hong Kong, People’s Republic of China; cwm6373{at}netvigator.com
View Full Text

Citation

Chan W, Lai TYY, Liu DTL, et al
Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study

Publication history

  • Accepted August 26, 2008
  • First published September 18, 2008.
Online issue publication 
February 09, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.